Title:
COMBINATION OF CD95/CD95L INHIBITION AND CANCER IMMUNOTHERAPY
Document Type and Number:
WIPO Patent Application WO/2015/197874
Kind Code:
A3
Abstract:
The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.
More Like This:
Inventors:
KUNZ CLAUDIA (DE)
FRICKE HARALD (DE)
HÖGER THOMAS (DE)
GAMER JUERGEN (DE)
FRICKE HARALD (DE)
HÖGER THOMAS (DE)
GAMER JUERGEN (DE)
Application Number:
PCT/EP2015/064762
Publication Date:
March 17, 2016
Filing Date:
June 29, 2015
Export Citation:
Assignee:
APOGENIX GMBH (DE)
International Classes:
A61P35/00; C07K16/28; C07K14/705
Other References:
ORBACH ARIEL ET AL: "CD40.FasL and CTLA-4.FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling", AMERICAN JOURNAL OF PATHOLOGY, THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 177, no. 6, 1 December 2010 (2010-12-01), pages 3159 - 3168, XP009155963, ISSN: 1525-2191
HUANG J-H ET AL: "CTLA-4-FAS LIGAND FUNCTIONS AS A TRANS SIGNAL CONVERTER PROTEIN IN BRIDGING ANTIGEN-PRESENTING CELLS AND T CELLS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 13, no. 4, 1 April 2001 (2001-04-01), pages 529 - 539, XP001147390, ISSN: 0953-8178, DOI: 10.1093/INTIMM/13.4.529
HO MING-YI ET AL: "Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 JUL 2008, vol. 123, no. 1, 1 July 2008 (2008-07-01), pages 123 - 133, XP055215606, ISSN: 1097-0215
ORBACH ARIEL ET AL: "CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 179, no. 11, 1 December 2007 (2007-12-01), pages 7287 - 7294, XP002668354, ISSN: 0022-1767
ANA MARTIN-VILLALBA ET AL: "CD95 in cancer: tool or target?", MOLECULAR MEDICINE TODAY, vol. 19, no. 6, 1 June 2013 (2013-06-01), pages 329 - 335, XP055216645, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2013.03.002
HUANG J-H ET AL: "CTLA-4-FAS LIGAND FUNCTIONS AS A TRANS SIGNAL CONVERTER PROTEIN IN BRIDGING ANTIGEN-PRESENTING CELLS AND T CELLS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 13, no. 4, 1 April 2001 (2001-04-01), pages 529 - 539, XP001147390, ISSN: 0953-8178, DOI: 10.1093/INTIMM/13.4.529
HO MING-YI ET AL: "Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 JUL 2008, vol. 123, no. 1, 1 July 2008 (2008-07-01), pages 123 - 133, XP055215606, ISSN: 1097-0215
ORBACH ARIEL ET AL: "CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 179, no. 11, 1 December 2007 (2007-12-01), pages 7287 - 7294, XP002668354, ISSN: 0022-1767
ANA MARTIN-VILLALBA ET AL: "CD95 in cancer: tool or target?", MOLECULAR MEDICINE TODAY, vol. 19, no. 6, 1 June 2013 (2013-06-01), pages 329 - 335, XP055216645, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2013.03.002
Attorney, Agent or Firm:
HEUBECK, Christian (Postfach 860 820, München, DE)
Download PDF: